Shared Decision Making for Antipsychotic Medications

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-30
SponsorNew York State Psychiatric Institute

About this trial

This study aims to provide an evidence-based shared decision making intervention for antipsychotic medications, the Antipsychotic Medication Decision Aid (APM-DA), for individuals experiencing early psychosis and provide, for the first time, an understanding of the shared decision making mechanism of action.

Eligibility criteria

Qualifiers

Ages 18 to 30 who have experienced nonaffective psychosis with a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, other specified/unspecified schizophrenia spectrum and other psychotic disorders (ICD-10-CM Diagnosis Code F20.x)

Current/past experiences with antipsychotic medications (APM; e.g., currently taking any antipsychotic medication, stopped taking, or considering stopping).

Receive FEP treatment in one of OnTrackNY clinics/sites randomized to intervention or treatment as usual (TAU) - Willing to participate in research interviews after each APM visit during the study period (3 months)

Disqualifiers

Unable to provide informed consent

No experience with APM

Not fluent (speaking, reading, writing) in English

Trial design

Treatments tested in this trial

  • The Antipsychotic Medication Decision Aid (APM-DA)

Treatment groups

120 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators